Blue Note logo


Creating a New Way Forward

Working closely with leading cancer centers, community oncology clinics, and teams of patients, Blue Note is developing clinically validated prescription digital therapeutics to help reduce anxiety, depression, and other distress related to cancer.


Laura Chavaree, MSW

Head of Patient Engagement

Tim Clark

Director of Engineering

Alexia Downs

Director, Patient Service Center

Geoff Eich


Mark Elfers

Head of Finance & Operations

Jen Feng

Senior Manager, Product Management

Elliott Harris

Patient Service Center Operations Lead

Lindsay Huffman

Key Account Manager

Patrick Kwon

Project Manager, Product Management

Rick Lit

Head of Scientific Operations

Michael Malecki, PhD

Head of Access & Reimbursement

Michael McKinley

Head of Product Development

Angela Perez

Key Account Manager

George Romanko

Head of HR & Talent

Michelle Rubin-Onur, PhD

Regulatory Lead

Dianne Shumay, PhD

Head of Behavioral Science

Kevin Wyllie

Quality Assurance Engineer

Board of Directors

Gena Cook

Director, Board of Directors

Geoff Eich

Blue Note Therapeutics

Andrew Firlik, MD

Jazz Venture Partners

John Harris

Jazz Venture Partners

Marcus Neubauer, MD

The US Oncology Network

Board of Advisors

Michael Antoni, PhD

Sylvester Comprehensive Cancer Center

Bio  Research

William Breitbart, MD

Memorial Sloan Kettering Cancer Center

Bio  Research

Patricia Ganz, MD

UCLA Jonsson Comprehensive Cancer Center

Bio  Research

Kevin Knopf, MD

UCSF Institute for Health Policy

Bio  Research

Lidia Schapira, MD

Stanford University Medical Center

Bio  Research

Betina Yanez, PhD

Northwestern University Feinberg School of Medicine

Bio  Research

Our Pipeline

Blue Note's products will serve all cancer patients, from early stage through survivorship, in both the in-patient and out-patient settings.

Product Candidate Disease Progression Development Proof of Concept Pivotal Trial FDA Review
BNT001 Early - Mid Stage  
BNT200 Acute In-patient    
BNT300 Late Stage      
BNT400 Survivorship      
Product Candidate Disease Progression Status
BNT001 Early - Mid Stage 2
BNT200 Acute In-patient 1
BNT300 Late Stage 0
BNT400 Survivorship 0
0 = Development
1 = Proof of Concept
2 = Pivotal Trial
3 = FDA Review

We Can't Do This Alone

Blue Note Therapeutics is honored to work with the National Comprehensive Cancer Network (NCCN) and other leading cancer care organizations in our quest to help cancer patients live better.